Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,663 total articles
ODDITY Tech Ltd. reported Q2 2026 net revenue of $181 million, down 25% year-over-year, with adjusted EBITDA of $13 million and net income of $13 million. The company highlighted strong revenue growth in its SpoiledChild brand and promising early results from METHODIQ. It is addressing a technical advertising issue with its largest partner affectin…
X4 Pharmaceuticals, a US-based biotech firm focused on rare hematology diseases, will take part in a management fireside chat at the 2026 Wells Fargo Healthcare Conference. The company is developing and commercializing mavorixafor, an oral CXCR4 antagonist currently approved in the US and undergoing pivotal Phase 3 trials for chronic neutropenia. T…
Autolus Therapeutics announced that the FDA granted RMAT designation to its T cell therapy candidate obecabtagene autoleucel (obe-cel) for treating systemic lupus erythematosus (SLE) and lupus nephritis (LN), accelerating development and regulatory review. The company plans further clinical data presentations and continues enrollment in a pivotal P…
Pyxis Oncology reported positive updated results from its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The study showed a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months,…
Rezolute announced that the FDA review of their Phase 3 sunRIZE study data for their drug ersodetug in treating congenital hyperinsulinism (HI) is ongoing without a defined timeline. While the study did not meet its primary endpoint for statistical significance, secondary analyses indicate glycemic improvements. The open-label extension phase conti…
Kura Oncology has established Caspian Therapeutics, a separately financed subsidiary focused on advancing KO-7246, a next-generation menin inhibitor designed for diabetes and cardiometabolic diseases. Caspian raised $50 million led by BVF Partners and supported by key biotech investors including Eli Lilly. Preclinical studies show promising results…
Satellos Bioscience announced that their lead oral small molecule drug candidate, previously known as SAT-3247, has been assigned the International Nonproprietary Name (INN) 'forazapadin.' The drug targets AAK1 to promote muscle regeneration and is currently in Phase 2 clinical trials for Duchenne muscular dystrophy (DMD), with plans to initiate a …
Aya Gold & Silver released an updated 2026 Preliminary Economic Assessment for its Boumadine polymetallic project in Morocco, showing a more than doubling of the after-tax net present value to $3.5 billion and an internal rate of return of 93%. The project life extends to 14 years with improved payable metal production and capital efficiency. The u…
INLIF LIMITED announced that its Extraordinary General Meeting of Shareholders originally scheduled for September 8, 2026, was adjourned due to insufficient shareholder attendance to meet quorum requirements. The meeting is set to reconvene on September 15, 2026. Previously submitted votes remain valid, and shareholders who have not yet voted are e…
Xanadu Quantum Technologies Limited has entered into a collaboration with ASML to develop advanced lithography techniques aimed at reducing optical losses in photonic quantum computing chips. This partnership seeks to address critical challenges in achieving fault-tolerant and error-corrected quantum hardware, accelerating progress toward utility-s…
Eledon Pharmaceuticals announced an upcoming oral presentation at the International Congress of The Transplantation Society showcasing long-term safety and efficacy data of its lead investigational drug, tegoprubart, for preventing kidney transplant rejection. The data come from the Phase 2 BESTOW trial and its extension, highlighting the drug's po…
Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b norovirus challenge study evaluating CDI-988 as a preventive and treatment for norovirus infections. This study is the first clinical trial of a direct-acting antiviral specifically targeting norovirus, aiming to address a significant unmet medical need. CDI-988 has sho…
OKYO Pharma Limited announced presentations at the Ophthalmology Futures European Forum and ESCRS iNovation Day, highlighting the advancement of its lead drug urcosimod in treating neuropathic corneal pain. The company also reported positive feedback from the FDA validating its regulatory pathway and a strengthened cash position, supporting the upc…
Can-Fite BioPharma announced publication of a peer-reviewed case report detailing the successful treatment of a patient with advanced decompensated liver cirrhosis using their drug Namodenoson, resulting in resolution of ascites and regression of esophageal varices. The patient remained clinically stable for 28 months on treatment before undergoing…
Telix Pharmaceuticals Limited announced that its senior executives will present at the Morgan Stanley 24th Annual Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company, a global radiopharmaceutical leader in cancer theranostics, aims to showcase its commercial progress and future plans to investo…
Einride AB announced a strategic partnership with UNIQAI Systems to enhance its autonomous logistics platform with AI-driven mission planning and operational decision-making capabilities tailored for defense and national security clients. Building on its existing autonomous freight technology and previous collaborations, Einride aims to address a s…
MannKind Corporation has entered into a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, a rapid-acting, short-duration inhaled GLP-1 receptor agonist for weight management. MannKind will provide pharmaceutical development and manufacturing support through Phase 1b trials, receive equity in Rose Pharma, …
Sysco Corporation reaffirmed its fiscal 2027 financial guidance with expected adjusted EPS growth of 9%-11% and announced a new $500 million multiyear AI-powered efficiency program aimed to reduce structural costs by fiscal 2029. The company also raised its mid-term financial targets for net sales and adjusted EPS growth for fiscal years 2028 and 2…
RadNet, Inc., a leading US outpatient imaging services provider, announced a free webinar on September 19, 2026, focused on prostate cancer risk, screening, diagnosis, and treatment advancements, including the use of prostate MRI and AI. The event aims to educate men and families during Prostate Cancer Awareness Month by featuring expert panelists …
KBR's Mission Technology Solutions division, to be spun off as Trinzic in January 2027, has been awarded a three-year contract to deliver advanced radio frequency engineering and manufacturing capabilities for a U.S. government customer. This contract reinforces KBR's longstanding partnership and positions the company strategically in national secu…
Radware Ltd. (NASDAQ: RDWR) released its H1 2026 Global Threat Analysis Report revealing a sharp increase in cyberattack activities, including a 110.6% rise in Web DDoS attacks and a doubling of malicious web application and API attacks compared to 2025. The report emphasizes rapid exploitation of vulnerabilities, accelerated by AI technologies, an…
RadNet, Inc., a leading US provider of diagnostic imaging services and related technology solutions, announced that its Executive Vice President and CFO, Mark Stolper, will present at the Morgan Stanley 24th Annual Global Healthcare Conference. The company operates a large network of outpatient imaging centers across multiple US states and offers A…
Titan Mining Corporation announced substantial advancements in federal and state permitting processes for its Kilbourne Graphite Project in New York as it remains on track for commercial natural flake graphite production by 2028. The project has received significant federal support, including financing interest from the U.S. Export-Import Bank, and…
BridgeBio Pharma announced positive results from their Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia, demonstrating benefits beyond increased growth including stabilization of sleep apnea, reduced ear infections, and improved body composition. The drug maintained sustained growth improvements and safety over three year…
Premium Catering (Holdings) Limited announced it received a NASDAQ notice for not timely filing its interim report for the half year ended December 31, 2025, resulting in non-compliance with NASDAQ listing rules. The company has 60 days to submit a compliance plan and potentially up to 180 days to regain compliance, failing which it risks delisting…
